NDAORALTABLETPriority Review
Approved
Jun 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
5/8 — Partial
Priority Review
ALBENZA (albendazole) by Teva is cytochrome p450 1a inducers [moa]. Approved for helminthiasis, neurocysticercosis, lymphatic filariasis and 9 more indications. First approved in 1996.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALBENZA (albendazole) is an oral anthelmintic tablet approved in 1996 that works by inducing cytochrome P450 1A enzymes to disrupt helminth metabolism. It treats a broad spectrum of parasitic worm infections including neurocysticercosis, lymphatic filariasis, ascariasis, hookworm, and soil-transmitted helminthiasis. The drug is particularly valuable in treating CNS parasitic infections where systemic bioavailability is critical.
LOE Approaching
With LOE approaching after 28+ years on market and moderate competitive pressure (30/100), the brand team is likely in defensive/optimization mode focused on maintaining share against generic erosion rather than growth initiatives.
Mechanism of Action
Cytochrome P450 1A Inducers
Pharmacologic Class:
Anthelmintic
Indications (12)
Worked on ALBENZA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.